Elias pour aujourd’hui et pour demain

Chevalier, Sophie; Privat, Jean-Marie

doi:10.4000/books.editionscnrs.1994

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although in some of these diseases the initial results were poor, in peritoneal disease from colorectal cancer the results were promising. Elias et al, for example, reported a 5-year survival of up to 50% in patients with peritoneal carcinomatosis who underwent CRS and HIPEC with intrabdominal Oxaliplatin and concomitant venous 5-FU 15 . Recently, the Prodige 7 study did not show survival benefits among patients in the group that underwent cytoreductive surgery alone compared with those in the group that underwent cytoreduction and HIPEC 16 .…”

Section: Kusamura Et Al Also Showed Better Overall Survival Resultsmentioning

confidence: 99%

Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Vallejo

Queiroz

Filho

et al. 2023

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

Peritoneal carcinomatosis (PC) indicates advanced stage cancer, which is generally associated with a poor outcome and a 6 to 12 months. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) is an option for treating patients with primary PC, such as mesothelioma, or secondary PC, such as colorectal cancer (CRC) or pseudomixoma. Until recently, such patients were deemed untreatable. Objective: The purpose of this study was to assess the results of CRS + HIPEC in patients with PC. Postoperative complications, mortality and survival rates were evaluated according to the diagnosis. Results: Fifty-six patients with PC, undergoing full CRS + HIPEC between October 2004 and January 2020, were enrolled. The mortality rate was 3.8% and the morbidity rate was 61.5%. Complications were significantly higher in proportion to the duration of surgery (p<0.001). The overall survival rates, as shown in the Kaplan-Meyer curve, were respectively 81%, 74% and 53% at 12, 24 and 60 months. Survival rates according to each diagnosis for the same periods were 87%, 82% and 47% in patients with pseudomixoma, and 77%, 72% and 57% in patients with CRC (log-rank 0.371, p=0.543). Conclusion: CRS with HIPEC is an option for pacients with primary or secondary PC. Although complication rates are high, a longer survival rate may be attained compared to those seen in previously published results; in some cases, patients may even be cured.

show abstract

Section: Kusamura Et Al Also Showed Better Overall Survival Resultsmentioning

confidence: 99%

Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Vallejo

Queiroz

Filho

et al. 2023

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

show abstract

“…Embora em algumas dessas doenças os resultados iniciais não tenham sido bons, na doença peritoneal proveniente do câncer colorretal os resultados foram promissores. Elias et al, por exemplo, relataram sobrevida de até 50% em 5 anos em pacientes portadores de carcinomatose peritoneal submetidos a CRS e HIPEC com Oxaliplatina intrabdominal e 5-FU venoso concomitante 15 . Recentemente o estudo Prodige 7, não demonstrou benefícios de sobrevida entre os pacientes do grupo que realizou apenas a cirurgia citorredutora comparados àqueles do grupo submetido à citorredução e HIPEC 16 .…”

Section: Vallejounclassified

Avaliação da morbimortalidade e da sobrevida em pacientes portadores de carcinomatose peritoneal submetidos a cirurgia citorretorredutora e quimioterapia hipertérmica intraperitoneal (HIPEC)

Vallejo

Queiroz

Filho

et al. 2023

Rev. Col. Bras. Cir.

View full text Add to dashboard Cite

RESUMO O diagnóstico de carcinomatose peritoneal (CP), indica um estágio avançado do câncer e em geral está associado a um mau prognóstico com sobrevida média variando de 6 a 12 meses. A cirurgia citorredutora (CRS) associada à quimioterapia intraperitoneal hipertérmica (HIPEC) tem sido descrita como uma opção de tratamento para os pacientes portadores de CP primária como nos portadores de mesotelioma, ou secundária como em portadores de cancer colorretal ou pseudomixoma, até recentemente considerados sem possibilidade terapêutica. Objetivo: Avaliar os resultados do tratamento de pacientes portadores de CP submetidos a CRS + HIPEC. Foram analisadas as taxas complicações pós-operatórias, mortalidade e a sobrevida desses pacientes. Resultados: Foram incluídos 56 pacientes com CP, submetidos a c CRS + HIPEC, no período de Outubro 2004 a Janeiro 2020. A taxa de mortalidade foi de 3,8% e taxa de morbidade de 61,5%, sendo a ocorrência de complicações significativamente maior quanto maior o tempo cirúrgico (p<0,001). A sobrevida global pela curva de Kaplan-Meyer foi de 81%, 74% e 53% em 12, 24 e 60 meses respectivamente. Já a sobrevida por diagnóstico nos mesmos períodos foi de 87%, 82%, 47% para os pacientes portadores de pseudomixoma e de 77%, 72% e 57% para pacientes portadores de câncer colorretal (Log -RANK 0,371, p=0,543). Conclusão: A CRS + HIPEC é uma opção de tratamento para pacientes portadores de CP primária ou secundária. Embora com taxa de complicações elevadas, pode proporcionar aumento da sobrevida quando comparado com resultados prévios da literatura e em alguns casos até a cura.

show abstract

Elias pour aujourd’hui et pour demain

Cited by 2 publications

References 0 publications

Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Assessing morbidity, mortality, and survival in patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy

Avaliação da morbimortalidade e da sobrevida em pacientes portadores de carcinomatose peritoneal submetidos a cirurgia citorretorredutora e quimioterapia hipertérmica intraperitoneal (HIPEC)

Contact Info

Product

Resources

About